AI assistant
BIODESIX INC — Director's Dealing 2023
Jul 27, 2023
34472_dirs_2023-07-26_76f230e4-1f34-44f1-a2ef-c5e3082cab8b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIODESIX INC (BDSX)
CIK: 0001439725
Period of Report: 2021-02-23
Reporting Person: Cowie Robin Harper (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-23 | Stock Options (Right to buy) | $20.67 | A | 61439 | Acquired | 2031-02-22 | Common Stock (61439) | Direct |
| 2021-02-23 | Stock Options (Right to buy) | $20.67 | A | 71524 | Acquired | 2031-02-22 | Common Stock (71524) | Direct |
| 2023-07-24 | Stock Options (Right to buy) | $20.67 | D | 61439 | Disposed | 2031-02-22 | Common Stock (61439) | Direct |
| 2023-07-24 | Stock Options (Right to buy) | $20.67 | D | 71524 | Disposed | 2031-02-22 | Common Stock (71524) | Direct |
| 2023-07-24 | Stock Options (Right to buy) | $1.2 | A | 27138 | Acquired | 2033-07-23 | Common Stock (27138) | Direct |
Footnotes
F1: This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021.
F2: This option was fully vested as of the grant date.
F3: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.
F4: The Reporting Person elected to participate in the Tender Offer and received 27,138 Replacement Options with an exercise price of $1.20 per share in exchange for 132,963 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.
F5: This Replacement Option vests as follows: 20,659 shares of Common Stock underlying this Replacement Option vest on August 1, 2024, and the remaining 6,479 shares of Common Stock underlying this Replacement Option vest in 31 successive, equal monthly installments beginning on August 1, 2024.